National Donor Day is celebrated annually every Valentine’s Day, and the Wisconsin Department of Transportation (WisDOT) is urging Wisconsinites to become organ donors. On ...

Shares of Kala Bio Inc. tumbled over 35% on Wednesday, on track for their worst single-day decline ever, after the company ...

ARLINGTON, Mass. - KALA BIO, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on developing treatments for rare and severe eye diseases, announced a change in its executive leadership on Monday ...

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

Mr. Iwicki stated, “I am proud of the work we have done at KALA utilizing our MSC-S platform, and I am very excited about the potential of our lead product candidate, KPI-012 for the treatment of PCED ...

Prothena (NASDAQ:PRTA – Get Free Report) and KALA BIO (NASDAQ:KALA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses ...

QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

A research team from the Eye & ENT Hospital of Fudan University, China, has developed a novel biocompatible nanoadhesive for ...

In this Healio Video Perspective from Hawaiian Eye 2025, I. Paul Singh, MD, discusses the benefits of using AlloFlo to create a cyclodialysis cleft in patients with glaucoma.

Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials ...

Using a consensus-based approach, they assessed 14 commonly used DED severity criteria. The panel agreed that following confirmed DED diagnosis, just two criteria, symptom-based assessment and corneal ...